Trevi Therapeutics, Inc. (TRVI) earnings date
Mar 16, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 39 days, typically, give or take 18 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Tue, Mar 17, 2026 | after close | 76 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | after close | 44 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Tue, Mar 18, 2025 | after close | 77 | 8-K |
What they guided beta
| Q3 FY2026 | "Exhibit 99.1 Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027 Notice of Allowance from the USPTO for patent application covering nalbuphine ER dosing in hepatically impaired patients with non-IPF ILD-related chronic cough, with pa" exhibit |
| Q3 FY2026 | "“We also recently aligned with the FDA on our non-IPF ILD-related chronic cough program and expect to initiate a Phase 2 dose-ranging trial in the first quarter of 2027." exhibit |
| Q3 FY2026 | "The 12-week fixed-dose OCEAN-2 trial , was initiated in the third quarter of 2026, and topline results are expected in the second half of 2027." exhibit |
| Q3 FY2026 | "The 52-week fixed-dose OCEAN-1 trial was initiated in the second quarter of 2026, and topline results are expected in the first half of 2028." exhibit |
| Q3 FY2026 | "The Company expects to initiate the trial in the first quarter of 2027, subject to review of the trial protocol by the FDA, and topline results are expected in the first half of 2028." exhibit |
| Q2 FY2026 | "Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET New Haven, Conn., August 6, 2026 – Trevi Therapeutics, Inc." exhibit |
| Q2 FY2026 | "We expect to initiate our second Phase 3 trial in IPF-related chronic cough during the third quarter and meet with the FDA regarding our planned non-IPF ILD-related chronic cough trial,” said Jennifer Good, President and CEO of Trevi Therapeutics." exhibit |
| Q2 FY2026 | "Topline data from the 52-week fixed dosing OCEAN-1 trial is expected in the first half of 2028." exhibit |
| Q2 FY2026 | "The Company plans to initiate the 12-week fixed dosing OCEAN-2 trial, in the third quarter of 2026, with topline results expected in the second half of 2027." exhibit |
| Q2 FY2026 | "The protocol includes a sample size re-estimation (SSRE) analysis once 50% of the participants complete treatment which is expected to occur in the fourth quarter of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TRVI
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TRVI
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TRVI/"><img src="https://veritasdata.dev/embed/TRVI.svg" alt="TRVI earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TRVI/)
Script
<script async src="https://veritasdata.dev/embed/TRVI.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TRVI"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.